CA2547881A1 - Prevention of and countermeasures against viral infection - Google Patents

Prevention of and countermeasures against viral infection Download PDF

Info

Publication number
CA2547881A1
CA2547881A1 CA002547881A CA2547881A CA2547881A1 CA 2547881 A1 CA2547881 A1 CA 2547881A1 CA 002547881 A CA002547881 A CA 002547881A CA 2547881 A CA2547881 A CA 2547881A CA 2547881 A1 CA2547881 A1 CA 2547881A1
Authority
CA
Canada
Prior art keywords
vitamin
virus
arginine
dose
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002547881A
Other languages
English (en)
French (fr)
Inventor
Fukumi Morishige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MORISHIGE Fumie
CHOKO CO Ltd
Life Science Institute Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2547881A1 publication Critical patent/CA2547881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002547881A 2003-11-20 2004-03-11 Prevention of and countermeasures against viral infection Abandoned CA2547881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003390695A JP4671092B2 (ja) 2003-11-20 2003-11-20 ウイルス感染予防および対策
JP2003-390695 2003-11-20
PCT/JP2004/003215 WO2005049007A1 (ja) 2003-11-20 2004-03-11 ウイルス感染予防および対策

Publications (1)

Publication Number Publication Date
CA2547881A1 true CA2547881A1 (en) 2005-06-02

Family

ID=34616351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002547881A Abandoned CA2547881A1 (en) 2003-11-20 2004-03-11 Prevention of and countermeasures against viral infection

Country Status (4)

Country Link
EP (1) EP1693058A4 (https=)
JP (1) JP4671092B2 (https=)
CA (1) CA2547881A1 (https=)
WO (1) WO2005049007A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656350B2 (ja) * 2008-10-08 2015-01-21 ポッカサッポロフード＆ビバレッジ株式会社 抗ｓａｒｓコロナウイルス剤及び抗ｓａｒｓコロナウイルス作用促進方法
WO2022089677A1 (de) * 2020-10-27 2022-05-05 Gosbert Weth Antivirale thrombosehemmende und tumorschädigende zusammensetzung mit arginin und thiocyanat
EP4313020A4 (en) * 2021-03-26 2025-01-29 Emory University MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRUS INFECTIONS AND RELATED COMPOUNDS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
JPS57100179A (en) * 1980-12-16 1982-06-22 Nissan Gosei Kogyo Kk Mixing method of particulate or granular saccharide with amino acid
JPS62221624A (ja) * 1986-03-24 1987-09-29 Shizuoka Pref Gov 魚類のウイルス病予防．治療方法
DE3728367C1 (de) * 1987-08-25 1988-09-01 Burkhard Steglich Mittel zur Immunisierung des menschlichen Koerpers bei HIV-Infektionen
US6608109B2 (en) * 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JPH10139683A (ja) * 1996-11-14 1998-05-26 Otsuka Pharmaceut Co Ltd 免疫賦活栄養補給組成物
JP2000281575A (ja) * 1999-03-25 2000-10-10 Kyokuto Internatl Corp 油脂被覆ビタミンｃ経口給与による、家畜の免疫力増強、並びにストレスの防除及び損耗を防止する方法
JP4601745B2 (ja) * 1999-08-23 2010-12-22 ハウスウェルネスフーズ株式会社 免疫賦活効果を相乗的に増強した製剤
WO2001015777A1 (en) * 1999-08-31 2001-03-08 Oxycal Laboratories, Inc. Pulmonary-administration of mineral ascorbates
US20020197352A1 (en) * 2001-04-02 2002-12-26 Pacifichealth Laboratories, Inc. Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise
DE10128910A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
CN1164267C (zh) * 2003-06-02 2004-09-01 中国科学院上海药物研究所 绿原酸的医学用途及它的制剂
CN1476836A (zh) * 2003-06-10 2004-02-25 中国科学院上海药物研究所 紫锥松果菊提取物的抗sars作用及其药物组合物

Also Published As

Publication number Publication date
EP1693058A4 (en) 2010-02-17
EP1693058A1 (en) 2006-08-23
WO2005049007A1 (ja) 2005-06-02
JP2005154283A (ja) 2005-06-16
JP4671092B2 (ja) 2011-04-13

Similar Documents

Publication Publication Date Title
Creager et al. Effect of captopril and enalapril on endothelial function in hypertensive patients.
US9327028B2 (en) Acetylcysteine compositions and methods of use thereof
NO332374B1 (no) Preparat som omfatter beta-hydroksy-beta-metylsmorsyre, L-arginin og L-lysin, og anvendelse av preparatet til fremstilling av ernaeringspreparater for bruk til dyr
RU2242242C2 (ru) Препаративная форма стабильного водного раствора интерферона, способ ее приготовления и использования
CA2547881A1 (en) Prevention of and countermeasures against viral infection
US20120052022A1 (en) Composition for oral health treatment and related methods of use
BRPI0307048B1 (pt) Composição farmacêutica sólida orodispersível de perindoprila, comprimido e uso de grânulos que consistem em lactose e amido co-secos
EP1543826A1 (en) Concentrated aqueous solution of ambroxol
JP2002275093A (ja) 局所麻酔用組成物
RU2738885C1 (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
WO2017009446A1 (en) Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action
WO2025167739A1 (zh) 化合物在制备预防和/或治疗高原病的药物中的应用
JP3415643B2 (ja) 筋ジストロフィー症治療薬
WO2021221537A1 (ru) Противо-sars-cov-2 вирусное средство антипровир
TW202203946A (zh) 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物
US20090209640A1 (en) Prevention of and countermeasures against viral infection
JP2022537792A (ja) 感染を処置するための組成物および相乗的方法
US20190216888A1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
Zohar et al. Is tranexamic acid indicated for total knee replacement surgery?
AU2002363874A1 (en) Use of desoxypeganine for treating clinical depression
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
PL367204A1 (en) Use of l-carnitine as stabilizing agent of proteins
WO2021205053A1 (es) Composición inyectable de melatonina para el tratamiento de enfermedades virales
HK1093441A (en) Prevention and measures for viral infection
CA2515505A1 (en) Inhibitor for perioperative blood sugar elevation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead